Retevmo and Appetite decreased - a phase IV clinical study of FDA data


Appetite decreased is reported only by a few people who take Retevmo.

The phase IV clinical study analyzes which people take Retevmo and have Appetite decreased. It is created by eHealthMe based on reports of 308 people who have side effects while taking Retevmo from the FDA, and is updated regularly.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Nov, 24, 2022

308 people reported to have side effects when taking Retevmo.
Among them, 3 people (0.97%) have Appetite decreased.

What is Retevmo?

Retevmo has active ingredients of selpercatinib. eHealthMe is studying from 308 Retevmo users for its effectiveness, alternative drugs and more.

What is Appetite decreased?

Appetite decreased (decreased appetite occurs when you have a reduced desire to eat) is found to be associated with 4,223 drugs and 4,253 conditions by eHealthMe.

Number of Retevmo and Appetite decreased reports submitted per year:

Could Retevmo cause Appetite decreased?

Gender of people who have Appetite decreased when taking Retevmo *:

  • female: 66.67 %
  • male: 33.33 %

Age of people who have Appetite decreased when taking Retevmo *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 0.0 %
  • 50-59: 0.0 %
  • 60+: 100 %

Common drugs people take besides Retevmo *:

  1. Carboplatin: 1 person, 33.33%
  2. Alimta: 1 person, 33.33%

Common side effects people have besides Appetite decreased *:

  1. Fatigue (feeling of tiredness): 2 people, 66.67%
  2. Weight Decreased: 1 person, 33.33%
  3. Urosepsis (secondary infection that occurs when a urinary tract infection spreads to the bloodstream): 1 person, 33.33%
  4. Urinary Tract Infection: 1 person, 33.33%
  5. Transaminases Increased: 1 person, 33.33%
  6. Polyneuropathy (neurological disorder that occurs when many peripheral nerves throughout the body malfunction simultaneously): 1 person, 33.33%
  7. Nausea (feeling of having an urge to vomit): 1 person, 33.33%
  8. High Blood Pressure: 1 person, 33.33%
  9. Hair Loss: 1 person, 33.33%
  10. General Physical Health Deterioration (weak health status): 1 person, 33.33%

Common conditions people have *:

  1. Lung Carcinoma Cell Type Unspecified Stage 0 (the lung cancer has not spread beyond the inner lining of the lung): 1 person, 33.33%
  2. Lung Cancer - Non-Small Cell (lung cancer): 1 person, 33.33%

* Approximation only. Some reports may have incomplete information.

Do you take Retevmo and have Appetite decreased?

Check whether Appetite decreased is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

How severe was Appetite decreased and when was it recovered:

Expand to all the drugs that have ingredients of selpercatinib:

Alternative drugs to, pros and cons of Retevmo:

Appetite decreased treatments and more:

COVID vaccines that are related to Appetite decreased:

Common drugs associated with Appetite decreased:

All the drugs that are associated with Appetite decreased:

Common conditions associated with Appetite decreased:

All the conditions that are associated with Appetite decreased:

How the study uses the data?

The study uses data from the FDA. It is based on selpercatinib (the active ingredients of Retevmo) and Retevmo (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).


WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: